Citations

Clear

1820 citation(s) found for "Israel, E".

Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Frishberg, Yaacov, Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Gansner, John M. , Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 416-416

10.1681/asn.20223311s1416a Get It

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis
Michael, Mini , Groothoff, Jaap W. , Shasha‐Lavsky, Hadas , Frishberg, Yaacov, Šimková, Eva, Sellier-Leclerc, Anne-Laure A., Devresse, Arnaud , Egziabher, Fitsum Guebre, Mourani, Chebl, Saqan, Rola , Willey, Richard G., Habtemarian, Bahru A., Bhan, Ishir , McGregor, Tracy L., Magen, Daniella , Lieske, John C. , Sellier‐Leclerc, Anne‐Laure , Bakkaloglu, Sevcan Azime , Singer, Richard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B2-B2

10.1681/asn.20213210s1b2a Get It

12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1
Saland, Jeffrey M. , Groothoff, Jaap W. , Frishberg, Yaacov, Hulton, Sally A., Koren, Michael J. , Overcash, Jeffrey S., Sellier-Leclerc, Anne-Laure A., Shasha‐Lavsky, Hadas , Magen, Daniella , Moochhala, Shabbir H. , Šimková, Eva, Sas, David J. , Meliambro, Kristin, Ngo, Taylor , Fujita, Kenji P. , Gansner, John M. , McGregor, Tracy L., Sellier‐Leclerc, Anne‐Laure , Deschênes, Georges , Hayes, Wesley Nathan , Fuster, Daniel Guido , Coenen, Martin , Garrelfs, Sander F. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: B8-B8

10.1681/asn.20203110s1b8c Get It

ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1)
Michael, Mini , Cochat, Pierre , Magen, Daniella , Hoff, William van’t , Sas, David J. , Schalk, Gesa, Shasha‐Lavsky, Hadas , Bae, Kyounghwa, Seddighzadeh, Ali, Garg, Pushkal, Vaishnaw, Akshay, McGregor, Tracy L., Fujita, Kenji P. , Frishberg, Yaacov, Deschênes, Georges , Hayes, Wesley Nathan

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 515-515

10.1681/asn.20203110s1515a Get It

Volume Progression and Imaging Classification of Polycystic Liver in ADPKD
Bae, Kyongtae T., Tao, Cheng , Feldman, Robert , Chapman, Arlene B., Brosnahan, Godela , Steinman, Theodore I., Braun, William E. , Mrug, Michal , Landsittel, Douglas , Yu, Alan S.L. , Torres, Vicente E. , Perrone, Ronald D. , Bennett, William M. , Harris, Peter C. , Abebe, Kaleab Z

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 500-500

10.1681/asn.20203110s1500c Get It

Overweight and Obesity Are Predictors of Pain in the HALT-PKD Studies
You, Zhiying , Brosnahan, Godela , Miskulin, Dana C. , Steinman, Theodore I., Braun, William E. , Chapman, Arlene B., Chonchol, Michel , Study, HALT-PKD, Wang, Wei Qiang , Gitomer, Berenice Y , Harris, Peter C. , Torres, Vicente E. , Abebe, Kaleab Z , Yu, Alan S.L. , Perrone, Ronald D. , Nowak, Kristen L. , Study, HALT-PKD

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 500-500

10.1681/asn.20203110s1500a Get It

PKD1 Compared with PKD2 Genotype and Cardiac Hospitalizations in the HALT-PKD Studies
You, Zhiying , Brosnahan, Godela , Steinman, Theodore I., Braun, William E. , Chapman, Arlene B., Chonchol, Michel , Steele, Cortney , Gitomer, Berenice Y , Harris, Peter C. , Torres, Vicente E. , Abebe, Kaleab Z , Yu, Alan S.L. , Perrone, Ronald D. , Nowak, Kristen L.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 488-488

10.1681/asn.20203110s1488a Get It

National Emergency Tele-Critical Care in a Pandemic: Barriers and Solutions
Pamplin, Jeremy , Gray, B.A. Mitchell, Quinn, Matthew , Little, Jeanette R , Subramanian, Sanjay , Farmer, Joseph C. , Ries, Michael, Scott, Benjamin , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team, Armaignac, Donna Lee , Polk, Travis M. , Colombo, Christopher J. , Participants, for the Governance Stakeholder Working Group and National Emergency Tele-Critical Care Network Team

Mayo Clinic

Critical Care Explorations | May 15, 2024 | Volume: 6 | Issue: 5 | Pages: e1091

10.1097/cce.0000000000001091 | PMID 38746740 Get It

The COVID-19 pandemic caused tremendous disruption to the U.S. healthcare system and nearly crippled some hospitals during large patient surges. Limited ICU beds across the country further exacerbated these challenges. Telemedicine, specifically tele-critical care (TCC), can expand a hospital’s clinical capabilities through remote expertise and increase capacity by offloading some monitoring to remote teams. Unfortunately, the rapid deployment of telemedicine, especially TCC, is constrained by multiple barriers. In the summer of 2020, to support the National Emergency Tele-Critical Care Network (NETCCN) deployment, more than 50 national leaders in applying telemedicine technologies to critical care assembled to provide their opinions about barriers to NETCCN implementation and strategies to overcome them. Through consensus, these experts developed white papers that formed the basis of this article. Herein, the authors share their experience and propose multiple solutions to barriers presented by laws, local policies and cultures, and individual perspectives according to a minimum, better, best paradigm for TCC delivery in the setting of a national disaster. Cross-state licensure and local privileging of virtual experts were identified as the most significant barriers to rapid deployment of services, whereas refining the model of TCC to achieve the best outcomes and defining the best financial model is the most significant for long-term success. Ultimately, we conclude that a rapidly deployable national telemedicine response system is achievable.
I-03 Dysregulation of T helper-type cytokines and interferons appear during early systemic lupus erythematosus pathogenesis and contribute to clinical disease development
Keith, Michael P. , Harley, John B., Munroe, Melissa E. , Lu, Rufei , Slight-Webb, Samantha R , Guthridge, Joel M. , Niewold, Timothy B. , Tsokos, George C. , James, Judith A.

Mayo Clinic

Interferons | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: A35.1-A35

10.1136/lupus-2016-000179.68 Get It

Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum
Sabbag, Avi , Aabel, Eivind W. , Castrini, Anna Isotta , Siontis, Konstantinos C. , Duthoit, Guillaume , Asirvatham, Samuel J. , Sehrawat, Ojasay, Kirkels, Feddo P. , Rav, Moshe , Peichl, Petr , Lim, H. , Martins, Raphaël P. , Font, Jonaz , Truong, Nguyen Ngoc Khoi , Estensen, Mette E , Laredo, Mikael , Duthoit, Guillaume , Kirkels, Feddo P , Beinart, Roy , Peichl, Petr , Sohns, Christian , Haugaa, Kristina , Asirvatham, Samuel J , Martins, Raphael , Aabel, Eivind W , Sabbag, Avi , Nizard, J. , Rosendael, Philippe J. van , Beinart, Roy , Haugaa, Kristina H.

Mayo Clinic

European Heart Journal | May 14, 2024 | Volume: 45 | Issue: 20 | Pages: 1831-1839

10.1093/eurheartj/ehae224 | PMID 38740526 Get It

Abstract Background and Aims Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA. Methods This retrospective international multi-centre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery. Results The authors included 18 women with AMVP from 11 centres. During 7.5 (interquartile range 5.8–16.6) years of follow-up, 37 malignant VAs occurred, of which 18 were pregnancy related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66, 95% confidence interval 1.23–5.76). Conclusions The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.